Pamidronate (Aredia)
Jump to navigation
Jump to search
General information
Class/mechanism: Bisphosphonate, inhibits osteoclast activity and bone resorption. Exact mechanism not understood, but is believed to also involve blocking dissolution of bone calcium phosphate (hydroxyapatite) crystals.[1][2][3]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Disease-specific information
Prostate cancer
- Smith MR, McGovern FJ, Zietman AL, Fallon MA, Hayden DL, Schoenfeld DA, Kantoff PW, Finkelstein JS. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med. 2001 Sep 27;345(13):948-55. link to original article PubMed
Patient drug information
History of changes in FDA indication
- 10/31/1991: Initial FDA approval
Also known as
- Generic name: pamidronate disodium omega
- Brand name: Aredia, Padium, Pamisol